Interstitial lung disease following certolizumab pegolPEARCE, Fiona; JOHNSON, Simon R; COURTNEY, Philip et al.Rheumatology (Oxford. Print). 2012, Vol 51, Num 3, pp 578-580, issn 1462-0324, 3 p.Article

The importance of the patients' experience of RA compared with clinical measures of disease activityTAYLOR, Pc.Clinical and experimental rheumatology (Testo stampato). 2010, Vol 28, Num 3, issn 0392-856X, S28-S31, SUP59Article

Use of biofluorescence imaging to compare the distribution of certolizumab pegol, adalimumab, and infliximab in the inflamed paws of mice with collagen-induced arthritisPALFRAMAN, Roger; AIREY, Michael; MOORE, Adrian et al.Journal of immunological methods. 2009, Vol 348, Num 1-2, pp 36-41, issn 0022-1759, 6 p.Article

Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trialSTRAND, Vibeke; SMOLEN, Josef S; VAN VOLLENHOVEN, Ronald F et al.Annals of the rheumatic diseases. 2011, Vol 70, Num 6, pp 996-1002, issn 0003-4967, 7 p.Article

Dose Escalation of Certolizumab Pegol From 200 Mg to 400 Mg Every Other Week Provides No Additional Efficacy in Rheumatoid Arthritis: An Analysis of Individual Patient-Level DataCURTIS, Jeffrey R; CHEN, L; LUIJTENS, K et al.Arthritis and rheumatism. 2011, Vol 63, Num 8, pp 2203-2208, issn 0004-3591, 6 p.Article

Certolizumab pegol for the treatment of crohn's diseaseSANDBORN, William J; FEAGAN, Brian G; STOINOV, Simeon et al.The New England journal of medicine. 2007, Vol 357, Num 3, pp 228-238, issn 0028-4793, 11 p.Article

Maintenance therapy with certolizumab pegol for Crohn's diseaseSCHREIBER, Stefan; KHALIQ-KAREEMI, Mani; LAWRANCE, Ian C et al.The New England journal of medicine. 2007, Vol 357, Num 3, pp 239-250, issn 0028-4793, 12 p.Article

Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTXCHOY, Ernest; MCKENNA, Frank; VENCOVSKY, Jiri et al.Rheumatology (Oxford. Print). 2012, Vol 51, Num 7, pp 1226-1234, issn 1462-0324, 9 p.Article

Nouvel anti-TNF: Le certolizumab pegolBRISSAUD, Philippe.Rhumatos. 2010, Vol 7, Num 59, pp 177-181, issn 1771-0081, 5 p.Article

Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trialKEYSTONE, Edward C; COMBE, Bernard; VAN DER HEIJDE, Desiree et al.Rheumatology (Oxford. Print). 2012, Vol 51, Num 9, pp 1628-1638, issn 1462-0324, 11 p.Article

Therapie mit Certolizumab pegol bei Patienten mit destruierender Arthritis = Treatment of patients with destructive arthritis with certolizumab pegolSCHMEISER, T; MÜLLER- LADNER, U.Zeitschrift für Rheumatologie (Print). 2010, Vol 69, Num 7, pp 653-656, issn 0340-1855, 4 p.Article

Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trialSMOLEN, J; LANDEWE, R. B; STRAND, V et al.Annals of the rheumatic diseases. 2009, Vol 68, Num 6, pp 797-804, issn 0003-4967, 8 p.Article

Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD studyFLEISCHMANN, R; VENCOVSKY, J; VAN VOLLENHOVEN, R. F et al.Annals of the rheumatic diseases. 2009, Vol 68, Num 6, pp 805-811, issn 0003-4967, 7 p.Article

Predicting Future Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Features at 12 Weeks Associated With Low Disease Activity at 1 YearCURTIS, Jeffrey R; LUIJTENS, Kristel; KAVANAUGH, Arthur et al.Arthritis care and research. 2012, Vol 64, Num 5, pp 658-667, issn 0893-7524, 10 p.Article

Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with a re-treatment extensionREICH, K; ORTONNE, J.-P; GOTTLIEB, A. B et al.British journal of dermatology (1951). 2012, Vol 167, Num 1, pp 180-190, issn 0007-0963, 11 p.Article

Présentation et analyse des études cliniques du certolizumab pégol dans la polyarthrite rhumatoïde Place du certolizumab pégol dans la stratégie thérapeutique actuelle = Analysis of clinical trials of certolizumab in rheumatoid arthritis.Role of certolizumab pegol in the therapeutic strategyCOMBE, B.La Lettre du pharmacologue (Boulogne). 2010, Vol 24, Num 4, pp 140-146, issn 0984-452X, 7 p.Article

Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegolHAZES, Johanna M; TAYLOR, Peter; STRAND, Vibeke et al.Rheumatology (Oxford. Print). 2010, Vol 49, Num 10, pp 1900-1910, issn 1462-0324, 11 p.Article

Certolizumab pegol in the treatment of rheumatoid arthritis: a comprehensive review of its clinical efficacy and safetyMEASE, Philip J.Rheumatology (Oxford. Print). 2011, Vol 50, Num 2, pp 261-270, issn 1462-0324, 10 p.Article

Certolizumab Pegol for the Management of Crohn's Disease in AdultsRIVKIN, Anastasia.Clinical therapeutics. 2009, Vol 31, Num 6, pp 1158-1176, issn 0149-2918, 19 p.Article

American College of Rheumatology Hybrid Analysis of Certolizumab Pegol Plus Methotrexate in Patients With Active Rheumatoid Arthritis: Data From a 52-Week Phase III TrialVAN VOLLENHOVEN, R. F; FELSON, D; STRAND, V et al.Arthritis care and research. 2011, Vol 63, Num 1, pp 128-134, issn 0893-7524, 7 p.Article

Effect of Certolizumab Pegol With Methotrexate on Home and Work Place Productivity and Social Activities in Patients With Active Rheumatoid ArthritisKAVANAUGH, Arthur; SMOLEN, Josef S; EMERY, Paul et al.Arthritis care and research. 2009, Vol 61, Num 11, pp 1598-1606, issn 0893-7524, 9 p.Article

Les anti-TNF : toujours au cœur de l'actualité des rhumatismes inflammatoiresLa Lettre du rhumatologue. 2009, Num MARS, issn 0761-5027, 9 p., INFOS-VCONGRESSerial Issue

Certolizumab Pegol Plus Methotrexate Is Significantly More Effective Than Placebo Plus Methotrexate in Active Rheumatoid Arthritis : Findings of a Fifty-Two-Week, Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group StudyKEYSTONE, Edward; VAN DER HEIJDE, Désireé; PAVELKA, Karel et al.Arthritis and rheumatism. 2008, Vol 58, Num 11, pp 3319-3329, issn 0004-3591, 11 p.Article

Tuberculosis Risk in Patients Treated with Non-Anti-Tumor Necrosis Factor-α (TNF-α) Targeted Biologics and Recently Licensed TNF-α Inhibitors: Data from Clinical Trials and National RegistriesCANTINI, Fabrizio; NICCOLI, Laura; GOLETTI, Delia et al.Journal of rheumatology. 2014, Vol 41, pp 56-64, issn 0315-162X, 9 p., SUP91Article

Certolizumab Pegol: A TNF-α Antagonist for the Treatment of Moderate-to-Severe Crohn's DiseaseSMITH, Lisa S; NELSON, Michael; DOLDER, Christian R et al.The Annals of pharmacotherapy. 2010, Vol 44, Num 2, pp 333-342, issn 1060-0280, 10 p.Article